Search Immortality Topics:

Page 17«..10..16171819..3040..»


Category Archives: Global News Feed

PCI Biotech second half 2023 interim results

Oslo (Norway), 14 February 2024 – PCI Biotech (OSE: PCIB), today announces its interim second half 2023 results. Please find enclosed the interim report and presentation.

See original here:
PCI Biotech second half 2023 interim results

Posted in Global News Feed | Comments Off on PCI Biotech second half 2023 interim results

Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in…

Pratteln, Switzerland, February 14, 2024 – Santhera Pharmaceuticals (SIX: SANN) announces the publication of the paper “Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy” in the peer-reviewed journal Neurology [2]. The publication reports the results of the 48-week treatment with vamorolone in patients with DMD in the VISION-DMD study, supporting the long-term efficacy and safety profile of vamorolone and concluding that vamorolone was generally well tolerated, consistent with the 24-week study findings, as published previously in JAMA Neurology [3].

See original here:
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in...

Posted in Global News Feed | Comments Off on Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in…

Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update

Conference call and webcast scheduled for February 14, 2024, at 13:00 (CET)

Read more from the original source:
Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update

Posted in Global News Feed | Comments Off on Ultimovacs ASA Reports Fourth Quarter 2023 Financial Results and Provides General Business Update

Mendus AB Year-end Report for 2023

Press Release

Original post:
Mendus AB Year-end Report for 2023

Posted in Global News Feed | Comments Off on Mendus AB Year-end Report for 2023

PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

Lyon (France) and Cambridge (MA, US), January 18, 2024, at 10:05pm CET – PHAXIAM Therapeutics (Nasdaq & Euronext: PHXM), a biopharmaceutical company developing innovative treatments for severe and resistant bacterial infections, today announces its cash position as of December 31, 2023, and its financial calendar for 2024.

See the original post:
PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

Posted in Global News Feed | Comments Off on PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024

Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

– Data demonstrate early activity with casdozokitug/atezolizumab/bevacizumab; 38% objective response rate including three complete responses –

Excerpt from:
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium

Posted in Global News Feed | Comments Off on Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium